Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Pulmonary Sarcoidosis
2016-001255-49Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary sarcoidosis comparing Canakinumab with Placebo (2 arms). Primary endpoint: Change from baseline in percent predicted forced vital capacity (FVC). Started Jul 2016; status: completed.
02
Drugs
canakinumab
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on 2016-001255-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001255-49.